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Summary
Background Previous retrospective studies of paediatric ulcerative colitis have had limited ability to describe disease 
progression and identify predictors of treatment response. In this study, we aimed to identify characteristics associated 
with outcomes following standardised therapy after initial diagnosis.
Methods The PROTECT multicentre inception cohort study was based at 29 centres in the USA and Canada and 
included paediatric patients aged 4−17 years who were newly diagnosed with ulcerative colitis. Guided by the Pediatric 
Ulcerative Colitis Activity Index (PUCAI), patients received initial standardised treatment with mesalazine 
(PUCAI 10–30) oral corticosteroids (PUCAI 35–60), or intravenous corticosteroids (PUCAI ≥65). The key outcomes for 
this analysis were week 12 corticosteroid-free remission, defined as PUCAI less than 10 and taking only mesalazine, and 
treatment escalation during the 12 study weeks to anti-tumour necrosis factor α (TNFα) agents, immunomodulators, or 
colectomy among those initially treated with intravenous corticosteroids. We identified independent predictors of 
outcome through multivariable logistic regression using a per-protocol approach. This study is registered with 
ClinicalTrials.gov, number NCT01536535.
Findings Patients were recruited between July 10, 2012, and April 21, 2015. 428 children initiated mesalazine (n=136), oral 
corticosteroids (n=144), or intravenous corticosteroids (n=148). Initial mean PUCAI was 31·1 (SD 13·3) in children 
initiating with mesalazine, 50·4 (13·8) in those initiating oral corticosteroids, and 66·9 (13·7) in those initiating 
intravenous corticosteroids (p<0·0001 for between-group comparison). Week 12 outcome data were available for 
132 patients who initiated with mesalazine, 141 with oral corticosteroids, and 143 with intravenous corticosteroids. 
Corticosteroid-free remission with the patient receiving mesalazine treatment only at 12 weeks was achieved by 64 (48%) 
patients in the mesalazine group, 47 (33%) in the oral corticosteroid group, and 30 (21%) in the intravenous corticosteroid 
group (p<0·0001). Treatment escalation was required by nine (7%) patients in the mesalazine group, 21 (15%) in the oral 
corticosteroid group, and 52 (36%) in the intravenous corticosteroid group (p<0·0001). Eight patients, all of whom were 
initially treated with intravenous corticosteroids, underwent colectomy. Predictors of week 12 corticosteroid-free remission 
were baseline PUCAI less than 35 (odds ratio 2·44, 95% CI 1·41−4·22; p=0·0015), higher baseline albumin by 1 g/dL 
increments among children younger than 12 years (4·05, 1·90−8·64; p=0·00030), and week 4 remission (6·26, 
3·79−10·35; p<0·0001). Predictors of treatment escalation by week 12 in patients initially treated with intravenous 
corticosteroids included baseline total Mayo score of 11 or higher (2·59, 0·93−7·21; p=0·068 [retained in model due to 
clinical relevance]), rectal biopsy eosinophil count less than or equal to 32 cells per high power field (4·55, 1·62−12·78; 
p=0·0040), rectal biopsy surface villiform changes (3·05, 1·09−8·56; p=0·034), and not achieving week 4 remission 
(30·28, 6·36−144·20; p<0·0001).
Interpretation Our findings provide guidelines to assess the response of children newly diagnosed with ulcerative 
colitis to standardised initial therapy and identify predictors of treatment response and failure. These data suggest 
that additional therapeutic interventions might be warranted to improve early outcomes, especially in patients 
presenting with severe disease and requiring intravenous corticosteroids.
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Introduction
Paediatric ulcerative colitis is markedly heterogeneous 
with respect to age of onset, anatomical extent, and 
disease course, with some patients quickly and continually 
responding to initial therapies, others having intermittent 
periods of clinical remission and disease flare, and a small 
number being refractory to current therapies and requiring 
colectomy.1,2 Because of the absence of rigorous clinical 
trial data in children, the ideal initial treatment frameworks 
are poorly defined. Previous natural history studies are 
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limited in value because of their retrospective nature 
and largely non-standardised treatment approaches to 
new-onset disease. Evidence from a multicentre, 
uncontrolled retrospective study suggested that initial 
response to therapy could be an important predictive factor 
of long-term outcome.3 Previous research has identified 
initial endoscopic and clinical disease severity, disease 
extent, hypalbuminaemia, histopathology, and certain 
genetic polymorphisms as relevant markers of disease 
course.3−10 However, these studies have been hampered by 
the patient outcome being characterised without 
standardised treatment protocols and have largely focused 
on patients admitted to hospital with severe disease treated 
with intravenous corticosteroids.
The Predicting Response to Standardized Pediatric 
Colitis Therapy (PROTECT) study was initiated in 2012 to 
systematically examine the responses of children and 
adolescents who were newly diagnosed with ulcerative 
colitis to consensus-defined disease-severity-based treat-
ment regimens of mesalazine and corticosteroids, with 
uniform pretherapy criteria established to determine when 
escalation to additional therapy was required. We aimed to 
identify rates and predictors of week 52 corticosteroid-free 
remission with mesalazine main tenance therapy only 
after initial treatment with mesalazine or corticosteroids. 
Because crucial management decisions are often needed 
at, or shortly after, the time of diagnosis in children with 
moderate-to-severe ulcerative colitis, we focused this 
analysis on the early outcome of week 12 corticosteroid-
free remission. An improved understanding of the 
likelihood and predictors of standardised therapy could 
better inform initial treatment choices.
Methods
Study design and participants
PROTECT was a multicentre inception cohort study 
based at 29 centres in the USA and Canada. Informed 
consent or assent was obtained (written assent for 
children aged 9–17 years) in all cases and the study was 
approved by the local investigational review board at all 
investigative sites. The study protocol is available online.
Patients were recruited between July 10, 2012, and 
April 21, 2015 (appendix p 3). Children aged 4–17 years 
with a clinical history consistent with colonic 
inflammation (any combination of diarrhoea, bleeding, 
and abdominal pain) were eligible for study. Complete 
demographic, clinical, laboratory, and serological data 
were obtained, along with stool samples and diagnostic 
ileocolonoscopy and oesophagogastroduodenoscopy with 
rectal biopsies. Eligibility criteria were disease extent 
Research in context
Evidence before this study
Because of insufficient paediatric clinical trial data, the selection 
of initial therapy for children newly diagnosed with ulcerative 
colitis is largely based on clinical trial data and uncontrolled 
experiences in adults, and uncontrolled retrospective data in 
children. We searched PubMed with the MeSH terms “ulcerative 
colitis”, “corticosteroids”, “5-aminosalicylates”, “treatment”, 
and “outcomes” for studies published in English before 
Dec 31, 2016. We identified no systematic prospective studies 
of initial standardised therapy in treatment-naive children. 
This absence of information has led to imprecision in guidance 
for clinicians, as well as patients and their families, as to what to 
expect and when following initiation of 5-aminosalicylates and 
corticosteroids in children. Parameters to help establish choices 
and timings of additional medical therapy such as 
immunomodulators or biological drugs, with their attendant 
risks and costs, are currently lacking.
Added value of this study
We established important reference data on initial response to 
oral mesalazine, oral corticosteroids, and intravenous 
corticosteroids.We showed that only 34% of all patients 
achieved the ideal 12 week outcome of corticosteroid-free 
remission with mesalazine treatment only, ranging from 48% 
of children presenting with mild-to-moderate disease who were 
treated initially with mesalazine, to 33% with 
moderate-to-severe disease treated initially with oral 
corticosteroids, and 21% in children with severe disease who 
were admitted to hospital and treated with intravenous 
corticosteroids. The need for biological therapy and even 
colectomy by 12 weeks after diagnosis was largely confined to 
patients presenting with more severe disease requiring 
intravenous corticosteroids as their first therapy. The strongest 
predictor of corticosteroid-free remission by week 12 without 
the need for additional therapy was clinical remission at week 4, 
irrespective of corticosteroid status. Commonly measured 
baseline characteristics such as disease extent, relative rectal 
sparing, total Mayo score, and serum albumin were important 
factors in predictive models of early outcomes. Our data also 
show that characterisation of the extent of eosinophilic 
infiltrate and the architectural abnormality of surface villiform 
changes in the initial rectal biopsy also contributed substantially 
to our predictive models.
Implications of all the available evidence
Our study adds to the understanding of early clinical outcomes 
in ulcerative colitis in children and provides crucial information 
on what clinicians, patients, and families can expect following 
the start of current standard-of-care therapy in this population. 
Our modelling identified commonly obtained clinical and 
laboratory parameters that can be helpful in predicting disease 
course and can help to guide clinicians in choosing whether or 
not to add medical therapy beyond 5-aminosalicylates and 
corticosteroids early in the treatment period. Our data establish 
standards that can be used for comparisons of effectiveness 
with newly emerging therapies with higher costs and unknown 
risks and to determine the usefulness of additional genomic and 
microbial biomarkers for treatment response.
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beyond the rectum (ie, proctitis excluded), a baseline 
Pediatric Ulcerative Colitis Activity Index (PUCAI)11 score 
of at least 10, no previous therapy for colitis, and 
stool culture negative for enteric bacterial pathogens 
(Salmonella, Shigella, Campylobacter, Escherichia coli 
0157:H7) and Clostridium difficile to xin. A cl inical, 
endoscopic, and histological diagnosis of ulcerative colitis 
was made in accordance with previously established 
criteria.12 Note was taken of whether there was patchiness 
to the endoscopic appearance or relative rectal sparing 
(rectum macroscopically less involved than more 
proximal segments). When feasible, baseline colonoscopy 
was completed to the caecum and the terminal ileum was 
intubated. Exclusion criteria were clinical, endoscopic, 
radiological, or histological evidence of Crohn’s disease at 
any time with a minimum of 1 year follow-up, granuloma 
on any biopsies, use of any oral corticosteroid medications 
for non-gastrointestinal indications in the past 4 weeks, and 
other gastrointestinal or non-gastrointestinal disorders that 
would have interfered with the study-mandated therapeutic 
framework. Macroscopic or microscopic gastritis was not 
deemed to indicate Crohn’s disease unless deep ulcers or 
granuloma were present.
Procedures
Disease extent was classified as proctosigmoiditis, 
left-sided colitis (to the splenic flexure), extensive colitis 
(to the hepatic flexure), or pancolitis (beyond the hepatic 
flexure) by visual evidence. Patients with severe or 
fulminant disease at presentation who received a flexible 
sigmoidoscopy because of safety concerns were assigned 
to the extensive colitis group.
Clinical activity at diagnosis was established with the 
PUCAI11 (range 0−85, in increments of 5 points) and 
Mayo score (range 0−12).13 A PUCAI less than 10 denoted 
inactive disease or remission, 10−30 denoted mild 
disease, 35−60 denoted moderate disease, and 65 or 
higher denoted severe disease. The site endoscopist 
assigned a Mayo endoscopic subscore (range 0−3) using 
standardised photographs that had been distributed to all 
investigative sites.
A central pathologist (MHC) blinded to clinical data 
examined a single rectal biopsy from each patient 
and assessed histological features of chronicity and 
quantitated acute inflammation by the presence and 
extent of cryptitis, crypt abscesses, or both. Chronicity 
was assessed by the presence or absence of any one of 
mucin depletion, crypt distortion, crypt branching, crypt 
atrophy, and basal lymphocytosis. Paneth cell metaplasia, 
surface villiform changes, or basal lymphoid aggregates 
were recorded if present. The description of eosinophilic 
inflammation included the peak number of eosinophils 
per high-power field relative to a cut-point (>32 cells 
per high-power field) derived from a study of normal 
rectal biopsies in children.14
At baseline, laboratory tests were recorded from local 
site standard-of-care assessments, as available, within 
4 weeks before the initial ulcerative colitis treatment and 
not more than 2 days after the initiation of treatment. The 
variables assessed were haemoglobin, platelet count, 
white blood cell count, serum albumin, erythrocyte 
sedimentation rate, and C-reactive protein (CRP or 
high-sensitivity CRP [hsCRP]). Plasma albumin was 
measured at a central laboratory with ELISA (Cell Biolabs, 
San Diego, CA, USA) for participants with no available 
local serum value. 25-OH vitamin D was measured 
centrally from plasma collected at baseline.15 We report 
observed values of all laboratory studies with the exception 
of CRP, which we report with respect to the upper limit of 
normal (ULN) for the local laboratory. Faecal calprotectin16 
was measured centrally with ELISA (Buhlmann 
Laboratories, Schönenbuch, Switzerland) from stool 
samples collected before colonoscopy cleanout or at 
2 days or more after colonoscopy, but not more than 3 days 
after initial ulcerative colitis treatment. Faecal calprotectin 
less than 250 µg/g was deemed to suggest inactive disease. 
Faecal osteoprotegerin was measured centrally for a 
subset of participants who provided stool specimens that 
were kept cold after passage (continued cold custody) by 
use of 0·01% polysorbate 20 added to the extraction buffer 
in accordance with method published previously.17
Serological determination of perinuclear anti-neutrophil 
cytoplasmic antibodies (pANCA), anti-Saccharomyces 
cerevisiae antibodies (ASCA) IgG, ASCA IgA, anti-CBir1 
(anti-flagellin), and anti-outer membrane precursor 
protein C (anti-OmpC) was done at Cedars-Sinai Hospital 
(Los Angeles, CA, USA) by use of previously published 
methods.18 A pANCA titre of 100 or more endotoxin units 
per mL (EU/mL) was deemed to represent a high titre.
Depending on initial PUCAI score, patients received 
initial treatment with either mesalazine (mild disease), 
oral corticosteroids (moderate disease), or intravenous 
corticosteroids (severe disease), with treatment choice 
based on standardised guidelines with some physician 
discretion allowed (figure 1). The final choice of initial 
therapy was made by consensus of the treating physician, 
patient, and family. Guidelines stated that patients 
starting on mesalazine should have corticosteroids added 
to their treatment if disease activity did not improve. 
Patients initiated on oral or intravenous corticosteroids 
were guided to start mesalazine after 2 weeks of 
corticosteroids if disease activity was controlled. 
A detailed description of treatment guidelines, as well as 
mesalazine dosing tables, standardised corticosteroid 
tapering schedules, and use of adjunctive medical 
therapy (eg, rectal therapy) is provided in the appendix 
(p 5–7). Mesalazine was used under investigational new 
drug number 111863. Additional medical therapy in the 
first 12 weeks was defined as the use of an immuno-
modulator (thiopurine or methotrexate), calcineurin 
inhibitor (cyclosporin or tacrolimus), or anti-tumour 
necrosis factor α (TNFα) agent. The following guidelines 
were used to help to establish the need for additional 
medical therapy: disease refractory to intravenous 
corticosteroids within the first 14 days per physician 
discretion to enable the rapid step-up of therapy when 
needed for severely ill patients; no response to oral 
corticosteroids within 4 weeks of starting therapy; PUCAI 
that continued to be 35 or higher despite a minimum of 
2−4 weeks of at least 1 mg/kg per day of prednisone; 
failure to wean prednisone to below 0·5 mg/kg per day 
by week 6; absence of sustained response or remission 
with use of mesalazine as a maintenance agent; or an 
adverse reaction to mesalazine preventing its use as a 
maintenance agent. Intolerance to mesalazine (paradoxical 
disease worsening, pancreatitis, hepatitis, or other 
significant side-effects) that precluded its use as a 
maintenance agent constituted a treatment failure and 
prompted the use of additional medical therapy. The 
choice of additional therapy for any patient was at 
the discretion of the attending physician, irrespective of 
the reason. If an anti-TNFα agent and immunomodulator 
were started concomitantly, the anti-TNFα was deemed 
to be the primary additional therapy. Patients with 
medically uncontrollable disease underwent colectomy. 
Rectal therapy was used at the discretion of the clinician 
and patient. All patients on mesalazine received 
study-supplied Pentasa (Shire Pharmaceuticals/Pantheon, 
Greenville, NC, USA).
Participants were enrolled and all baseline assessments 
were completed before the initiation of therapy. 
Minimum follow-up was 1 year, ending in April, 2016. 
This report focuses on post-baseline assessments during 
the crucial initial 4 and 12 weeks of treatment after 
diagnosis, along with interim phone calls, visits, and 
hospital admissions, as needed. Visit assessments 
included PUCAI assessment, partial Mayo assessment 
(excluding the endoscopic subscore), clinical evaluation, 
and standard-of-care clinical laboratory tests. Stool 
samples and plasma for specialised laboratory 
assessments were collected at 4 and 12 weeks. We 
established visit windows to maximise follow-up 
observations. Week 4 assessments were made between 
days 21 and 49 and week 12 assessments occurred 
between days 60 and 120.
Outcomes
The primary outcome of the PROTECT study is week 52 
corticosteroid-free remission without the need for 
additional medical therapy or colectomy, which will be 
reported at a later date. Given that crucial management 
decisions are often required at the time of diagnosis in 
moderately-to-severely ill children we focused this 
analysis on the early outcome of week 12 corticosteroid-
free remission (PUCAI<10) with patients receiving only 
mesalazine and no corticosteroids for a minimum of 
2 weeks. Other outcomes were week 4 remission, 
irrespective of corticosteroids, week 12 corticosteroid-free 
Figure 1: Standardised study treatment guidelines
PUCAI=Pediatric Ulcerative Colitis Activity Index. TNF=tumour necrosis factor.
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remission in patients who had achieved week 4 clinical 
remission (sustained remission), week 12 corticosteroid-
free remission in patients who started on mesalazine 
and never required any corticosteroids (corticosteroids 
naive), week 12 corticosteroid-free remission with faecal 
calprotectin less than 250 µg/g, week 12 remission 
irrespective of corticosteroids, and escalation to 
additional medical therapy or colectomy at weeks 4 or 12. 
Serious adverse events were reviewed by an independent 
medical monitor. Safety data were reviewed quarterly by 
a data and safety monitoring board.
Statistical analysis
Data collection and reporting was done in accordance with 
the STROBE19 and TRIPOD20 guidelines for observational 
studies and the reporting of multivariable prediction 
models. A planned sample size of 430 patients was 
calculated to ensure at least 90% power to identify an odds 
ratio (OR) of at least 2·5 in predictive modelling, with 
p values of less than 0·05 being deemed statistically 
significant. We compared participant subgroups defined 
by initial ulcerative colitis treatment (mesalazine, oral 
corticosteroids, or intravenous corticosteroids) or outcome 
classification ( remission, a dditional m edical t herapy o r 
colectomy, or neither) for baseline factors and clinical 
outcomes using a χ² test or Fisher’s exact test for 
categorical assessments, a Mantel-Haenszel χ² test for 
ordinal categorical assessments, a t test for normally 
distributed continuous assessments, and a Wilcoxon 
rank-sum test for continuous assessments with skewed 
distributions. All tests were two-sided. We made no 
adjustment for multiple comparisons. We did the 
statistical analyses with SAS version 9.3.
We identified p redictors o f c linical o utcomes i n 
multivariable logistic regression models of the 
per-protocol population. Potential predictors for week 4 
outcomes included all baseline clinical and laboratory 
factors, whereas potential predictors of week 12 
outcomes included baseline factors, week 4 assessments, 
and change from baseline to week 4. We fitted models of 
week 12 corticosteroid-free remission and week 4 
remission for the full cohort of participants and for 
subgroups based on initial therapy. We also modelled 
escalation to additional medical therapy or colectomy at 
weeks 4 and 12 for the subgroup of participants starting 
on intravenous steroids because that was the group for 
whom additional intervention was most common. We 
obtained adjusted ORs and 95% CIs from logistic 
regression of a best-fit set of predictors with a cutoff of a 
p value less than or equal to 0·06, which we chose 
because several consistent predictors had p values that 
were nominally greater than 0·05. Predictors were 
identified i n a  s tepwise f ashion a nd r efined th rough 
clinical review and internal validation to address 
over-fitting a nd m issing d ata v ia b ootstrapping a nd 
multiple imputation, as described in the appendix 
(pp 7–9). We assessed model fit with the area 
under 
curve (AUC) of the receiver operating characteristic 
(ROC) curve, R² (maximum rescaled; appendix p 8), and 
Hosmer-Lemenshow goodness of fit test.
Prediction models were affected by the pattern of 
missing data across assessments. Because of the 
percentage of missing values for CRP, faecal calprotectin, 
and faecal osteoprotegerin, we did not include these 
items in the multivariable models, irrespective of the 
strength of the unadjusted association, although we did 
include CRP and faecal calprotectin in the multiple 
imputation analysis.
This study is registered with ClinicalTrials.gov, 
NCT01536535, and is closed to new participants.
Role of the funding source
The funders of the study collaborated with the authors in 
finalising the study design, provided feedback throughout 
the period of data collection, and participated in data 
analysis, data interpretation, and  writing of the report. 
The manuscript was written by the PROTECT Study 
Publication Committee. All authors had access to the study 
data and reviewed and approved the final manuscript.
Results
467 patients enrolled in PROTECT between July 10, 2012, 
and April 21, 2015 (figure 2). The median enrolment per 
centre was 13 patients (range 2−47). 36 patients were 
removed from the study secondary to a change in 
diagnosis to Crohn’s disease (n=28) or a major protocol 
inclusion violation (four lacked informed consent, 
two had inadequate data collection, one had C difficile 
diagnosis at baseline, and one enrolled 3 weeks after 
colonoscopy). An additional patient who had a colonic 
perforation at diagnostic colonoscopy and two patients 
who refused medical therapy were also excluded, 
leaving 428 treated patients evaluable for outcome 
determination. Table 1 shows demographic, clinical, 
and laboratory characteristics categorised by initial 
therapy. Mean age was 12·7 years (SD 3·3), 216 (50%) of 
428 patients were male, 355 (83%) patients had extensive 
disease or pancolitis, and 351 patients (84% of 
420 patients with data on race) were white. More severe 
clinical and laboratory features were noted in patients 
receiving intravenous corticosteroids (initial mean 
PUCAI 66·9 [SD 13·7]) or oral corticosteroids 
(50·4 [13·8]) than in those initially treated with 
mesalazine (31·1 [13·3]; p<0·0001).
Missing data for initial standard-of-care laboratory 
values ranged from six (1%) of 428 patients for albumin, 
to 43 (10%) patients for erythrocyte sedimentation rate 
across other baseline laboratory markers, with the 
exception of CRP, for which data was missing from 
113 (26%) patients. Initial stool assessments were 
missing from 189 (44%) patients for faecal calprotectin 
and 250 (58%) patients for osteoprotegerin. Week 4 
stool assessments and standard-of-care blood laboratory 
assessments had more missing data. At baseline, data 
were missing from 61 (14%) patients for histology, 31 (7%) 
patients for serology, and 35 (8%) patients for vitamin D. 
Standard-of-care laboratory tests seemed to be more 
complete for participants with more severe disease. All 
participants had complete data for baseline PUCAI, 
Mayo score, and endoscopy assessments.
Outcome data were available for 422 (99%) of 
428 patients at week 4 and 416 (97%) patients at week 12. 
Average assessment times were at 4·1 weeks (SD 0·6; 
340 [82%] of 415 patients within days 25−34) and 
12·2 weeks (1·3; 331 [82%] of 403 patients within 
days 75−96). Patients who escalated to additional therapy 
(and therefore had a defined outcome), but subsequently 
discontinued the study did not attend the week 4 visit 
(n=7) or the week 12 visit (n=13). Seven participants 
(three by week 4 and four between weeks 4 and 12) were 
excluded from the predictive modelling because of 
treatment violations, including gaps in treatment of 
longer than 28 days (two patients) and escalation to 
additional therapy due to liver disease (two patients) or 
because of investigator choice without meeting a 
guideline specified by the standardised treatment 
algorithm (three patients).
286 (67%) of all 428 patients received the initial therapy 
indicated by the standardised PUCAI-based treatment 
framework, including 84 (82%) of 102 patients with 
PUCAI of 10−30 who received mesalazine, 96 (52%) of 
185 patients with PUCAI of 35−60 who received oral 
corticosteroids, and 106 (75%) of 141 patients with PUCAI 
of 65 or higher who received intravenous corticosteroids. 
Overall, 136 patients received mesalazine (mean initial 
therapy dose 67 mg/kg per day [SD 9]), 144 patients 
received oral corticosteroids (mean 0·9 mg/kg 
per day [0·3]), and 148 patients received intravenous 
corticosteroids (mean 1·0 mg/kg per day [0·4]). Rectal 
therapy (corticosteroid or mesalazine) was given at 
baseline to 12 (3%) patients, irrespective of other 
therapies. This number increased by week 4, when 
25 (6%) of 422 patients had received rectal mesalazine 
and 22 (5%) patients had received rectal corticosteroids, 
and increased further by week 12, when 45 (11%) of 
416 patients had received rectal mesalazine and 29 (7%) 
had received rectal corticosteroids, before use of any 
additional medical therapies.
By week 12, 376 (90%) of 416 participants had received 
mesalazine at some point and 310 (75%) had received 
mesalazine therapy for at least 8 weeks. At week 12, 
mesalazine was being used by 320 (77%) patients either 
alone (240 [58%] patients) or in conjunction with oral 
corticosteroids (80 [19%] patients). Mesalazine was 
discontinued in 29 (7%) patients because of intolerance 
or side-effects in 12 (3%) patients (one moderate rash, 
one mild rash, and 10 worsening of symptoms), 
ineffectiveness in 15 (4%) patients, and the patient’s 
choice in two (<1%) patients. Treatment-emergent 
adverse events before escalation of therapy beyond 
mesalazine or corticosteroids are shown in the 
appendix (p 25).
Figure 3 shows the main clinical outcomes for all 
enrolled patients by initial therapy. Week 4 remission 
occurred in 73 (54%) of 135 patients who initially started 
on mesalazine, 81 (57%) of 143 patients who initially 
started on oral corticosteroids, and 57 (40%) of 
148 patients who initially started on intravenous 
corticosteroids (p=0·0079; table 2). By week 12, 
corticosteroid-free remission was seen in 64 (48%) of 
132 patients in the mesalazine group, 47 (33%) of 
141 patients in the oral corticosteroid group, and 30 (21%) 
of 143 patients in the intravenous corticosteroid group 
(p<0·0001). Among the patients initiating the medication 
specified by the PUCAI-based standardised guideline, 
corticosteroid-free remission at week 12 was seen in 
Figure 2: Trial profile
*Includes three patients who received both oral corticosteroids and mesalazine 
and one patient who received intravenous corticosteroids for 1 day without being
admitted to hospital. †Includes 233 patients on both oral corticosteroids and 
mesalazine. ‡Includes 80 patients on both oral corticosteroids and mesalazine.
431 enrolled
3 treatment violations (not treated)
6 discontinued without additional therapy or
colectomy
428 included at baseline
136 initiated on mesalazine
144 initiated on oral steroids*
148 initiated on intravenous steroids
422 assessed at week 4
1 receiving no treatment
117 receiving mesalazine
256 receiving oral steroids†
3 receiving intravenous steroids
41 receiving additional therapy
4 underwent colectomy
416 assessed at week 12
5 receiving no treatment
240 receiving mesalazine
88 receiving oral steroids‡
1 receiving intravenous steroids
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Age (years) 12·7 (3·3) 12·8 (3·3) 12·5 (3·3) 12·7 (3·2) 0·73
≥12 years 289 (68%) 92 (68%) 96 (67%) 101 (68%) ··
Sex 0·079
Girls 212 (50%) 69 (51%) 61 (42%) 82 (55%) ··
Boys 216 (50%) 67 (49%) 83 (58%) 66 (45%) ··
Race or ethnicity
White 351/420 (84%) 113/134 (84%) 122/140 (87%) 116/146 (79%) ··
Non-white 69/420 (16%) 21/134 (16%) 18/140 (13%) 30/146 (21%) 0·21
Hispanic or Latino 38/424 (9%) 18/134 (13%) 9/143 (6%) 11/147 (7%) 0·085
Z score
Weight –0·1 (1·2) 0·0 (1·1) 0·0 (1·2) –0·3 (1·2) 0·037
Height 0·1 (1·0) 0·1 (1·0) 0·2 (0·9) –0·0 (1·0) 0·052
Body-mass index –0·2 (1·3) –0·0 (1·2) –0·2 (1·3) –0·4 (1·4) 0·035
Admitted to hospital at baseline 166 (39%) 4 (3%) 14 (10%) 148 (100%) <0·0001
Disease extent <0·0001
Proctosigmoiditis 29 (7%) 22 (16%) 4 (3%) 3 (2%) ··
Left-sided colitis 44 (10%) 28 (21%) 14 (10%) 2 (1%) ··
Extensive, pancolitis, or 
unassessable*
355 (83%) 86 (63%) 126 (88%) 143 (97%) ··
Total PUCAI (range 0−85 in increments 
of 5)
50·0 (19·9) 31·1 (13·3) 50·4 (13·8) 66·9 (13·7) <0·0001
10−30 (mild) 102 (24%) 84 (62%) 15 (10%) 3 (2%) ··
35−60 (moderate) 185 (43%) 50 (37%) 96 (67%) 39 (26%) ··
≥65 (severe) 141 (33%) 2 (1%) 33 (23%) 106 (72%) ··
Abdominal pain 354 (83%) 97 (71%) 122 (85%) 135 (91%) <0·0001
Diarrhoea 393 (92%) 104 (76%) 142 (99%) 147 (99%) <0·0001
Rectal bleeding 398 (93%) 117 (86%) 136 (94%) 145 (98%) <0·0001
Total Mayo score (0−12) 7·8 (2·5) 5·5 (1·8) 7·9 (1·7) 9·8 (1·7) <0·0001
0−6 125 (29%) 99 (73%) 23 (16%) 3 (2%) ··
7−9 183 (43%) 35 (26%) 93 (65%) 55 (37%) ··
≥10 120 (28%) 2 (1%) 28 (19%) 90 (61%) ··
≥11 71 (17%) 0 6 (4%) 65 (44%) <0·0001
Mayo endoscopic subscore (0−3) 2·2 (0·7) 1·8 (0·6) 2·2 (0·6) 2·6 (0·5) <0·0001
1 59 (14%) 43 (32%) 13 (9%) 3 (2%) ··
2 224 (52%) 79 (58%) 88 (61%) 57 (39%) ··
3 145 (34%) 14 (10%) 43 (30%) 88 (59%) ··
Relative rectal sparing 38/427 (9%) 17/136 (13%) 15/144 (10%) 6/147 (4%) 0·034
Macroscopic patchiness 37/427 (9%) 23/136 (17%) 8/144 (6%) 6/147 (4%) 0·00017
Cecal patch 29/397 (7%) 17/135 (13%) 10/136 (7%) 2/126 (2%) 0·0029
Non-specific macroscopic gastritis 114/420 (27%) 33/131 (25%) 28/143 (20%) 53/146 (36%) 0·0050
Microscopic gastritis 242/418 (58%) 59/129 (46%) 86/142 (61%) 97/147 (66%) 0·0023
Rectal biopsy eosinophilic inflammation 
(>32 cells per high-power field)
210/367 (57%) 64/116 (55%) 82/125 (66%) 64/126 (51%) 0·052
Rectal biopsy surface villiform changes 135/364 (37%) 31/115 (27%) 47/125 (38%) 57/124 (46%) 0·010
Rectal biopsy basal plasmacytosis 176/336 (52%) 51/111 (46%) 65/118 (55%) 60/107 (56%) 0·25
Haemoglobin (g/dL) 11·4 (2·2) 12·5 (1·8) 11·5 (2·1) 10·5 (2·2) <0·0001
<10 98/402 (24%) 8/122 (7%) 28/133 (21%) 62/148 (42%) ··
<12 231/402 (57%) 46/122 (38%) 77/133 (58%) 108/148 (73%) ··
Platelet count (×10⁹ cells per L) 372 (303−462) 319 (251−406) 376 (318−464) 411 (339−509) <0·0001
>500 77/399 (19%) 10/121 (8%) 28/133 (21%) 39/145 (27%) 0·00053
(Table 1 continues on next page)
40 (49%) of 82 patients initially treated with mesalazine, 
33 (34%) of the 96 treated with oral corticosteroids, 
and 22 (22%) of the 102 treated with intravenous 
corticosteroids. In a post-hoc analysis we noted that 
85 (20%) of 416 patients had a PUCAI of less than 10 at 
week 12 but were still on corticosteroids (43 [10%] 
patients) or had discontinued corticosteroids less than 
2 weeks previously (42 [10%] patients). In patients still 
receiving oral corticosteroids at week 12, the median dose 
was 0·3 mg/kg per day (IQR 0·19–0·51) of prednisone 
equivalent. One patient was receiving intravenous 
corticosteroids. Outcome data stratified by whether or 
not the patient initiated the drug specified by the 
PUCAI-based standardised guideline are shown in the 
appendix (p 10).
By week 4, four (3%) of 143 patients who initiated oral 
corticosteroids required infliximab and 36 (25%) of 
144 patients who initiated intravenous corticosteroids 
required infliximab (35 patients; p<0·0001) or a 
calcineurin inhibitor (one patient). Immunomodulator 
monotherapy was started in one (1%) of 135 patients in 
the mesalazine group, two (1%) of 143 patients in the 
oral corticosteroid group, and 1 (1%) of 144 patients in 











(Continued from previous page)
White blood count (× 10⁹ cells per L) 9·2 (7·2–12·1) 7·8 (6·5–9·3) 9·2 (7·0–11·1) 11·3 (8·7–14·9) <0·0001
>12 100/397 (25%) 10/119 (8%) 23/133 (17%) 67/145 (46%) ··
Erythrocyte sedimentation rate 
(mm/h)
25 (12–42) 15 (8–24) 25 (12–39) 38 (21–57) <0·0001
≤20 165/385 (43%) 79/118 (67%) 53/125 (42%) 33/142 (23%) ··
>40 102/385 (26%) 8/118 (7%) 29/125 (23%) 65/142 (46%) ··
CRP/hsCRP ··
>ULN 144/315 (46%) 18/89 (20%) 44/102 (43%) 82/124 (66%) <0·0001
>2 × ULN 97/315 (31%) 10/89 (11%) 27/102 (26%) 60/124 (48%) <0·0001
Albumin (g/dL) 3·7 (0·7) 4·0 (0·7) 3·7 (0·6) 3·4 (0·7) <0·0001
<3·5 138/422 (33%) 25/133 (19%) 37/142 (26%) 76/147 (52%) ··
Faecal calprotectin (µg/g)† 2352 (1202–3928) 1692 (851–3631) 2663 (1202–3664) 3202 (1495–4384) 0·030
≥250 226/239 (95%) 64/74 (86%) 73/75 (97%) 89/90 (99%) ··
Faecal osteoprotegerin (pg/mL)† 424 (31–3259) 119 (31–1677) 318 (31–1638) 1491 (169–6830) 0·0012
>1000 70/178 (39%) 15/53 (28%) 18/59 (31%) 37/66 (56%) ··
25-OH vitamin D (ng/mL) 28·5 (23·9–34·8) 28·1 (23·8–34·0) 29·9 (25·2–36·4) 27·4 (22·4–33·0) 0·032
<20 (deficient) 42/393 (11%) 14/125 (11%) 10/132 (8%) 18/136 (13%) ··
pANCA (EU/mL)
Positive titre 259/397 (65%) 73/125 (58%) 90/135 (67%) 96/137 (70%) 0·13
≥100 75/397 (19%) 17/125 (14%) 28/135 (21%) 30/137 (22%) 0·18
OmpC 7·4 (5·3−11·2) 7·2 (5·1−11·2) 7·3 (5·7−10·2) 7·5 (5·3−11·6) 0·76
Positive titre 21/397 (5%) 8/125 (6%) 7/135 (5%) 6/137 (4%) 0·76
≥12 81/397 (20%) 25/125 (20%) 25/135 (19%) 31/137 (23%) 0·70
CBir1-postive titre 76/397 (19%) 27/125 (22%) 27/135 (20%) 22/137 (16%) 0·50
Data are mean (SD), n (%), n/N (%), or median (IQR) unless noted otherwise. n/N values show missing data. p values comparing groups are from a χ² or Fisher’s exact test for 
categorical variables, a Mantel-Haenszel χ² test for ordinal variables, and ANOVA or Kruskal-Wallis test for continuous variables. PUCAI=Pediatric Ulcerative Colitis Activity 
Index. CRP=C-reactive protein. ULN=upper limit of normal. EU=endotoxin units. pANCA=perinuclear anti-neutrophil cytoplasmic antibody. OmpC=outer membrane 
precursor protein C. CBir1=flagellin. *Unassessable represents severe or fulminant disease at presentation and that the clinician did a flexible sigmoidoscopy for safety 
concerns. †Results limited to stool collected before 4 days of initial treatment, and before or after colonoscopy cleanout.
Table 1: Demographic and clinical characteristics by initial therapy

































in the intravenous corticosteroid group, had colectomy 
by week 4, with three not responding to infliximab and 
one having colectomy after intravenous corticosteroids 
only. Eight patients, all in the intravenous corticosteroid 
group, required colectomy by week 12. Five of the 
82 patients requiring additional medical therapy did so 
because of intolerance or side-effects t hought t o b e 
related to mesalazine (one moderate rash and four 
worsening of symptoms). Seven other patients stopped 
mesalazine because of adverse reactions, but did not 
receive additional therapy beyond corticosteroids by 
week 12 (appendix p 25). Two additional patients 
received a thiopurine because of concomitant liver 
disease.
Clinical and laboratory measures reflecting increasing 
disease severity at baseline were associated with worse 
outcomes (table 3). Of particular note were two 
histological features: a baseline rectal biopsy peak 
eosinophil count of more than 32 cells per high-power 
field was associated with better outcomes and surface 
villiform changes were associated with worse outcomes. 
Age, sex, ethnicity, body-mass index, pANCA positivity, 
and baseline faecal calprotectin were not associated 
with outcome. However, week 4 faecal calprotectin was 
associated with week 12 outcome. Median baseline 
25-OH vitamin D was lower in patients requiring
additional medical therapy by week 12 compared with
the other groups (p=0·047), but 25-OH vitamin D lower
than 20 ng/mL was not associated with outcome.
Relationships with week 12 outcomes for the three initial
therapy groups are shown in the appendix (pp 11−13),
and associations between baseline characteristics and
week 4 clinical outcomes are also shown for the full
cohort (appendix p 14) and for each therapy group
(appendix pp 15−17).
A multivariable model of baseline characteristics 
associated with week 4 remission for all three initial 













Patients assessed for outcomes 422 (99%)* 135 (99%)* 143 (99%)* 144 (97%)* ··
Remission 
(PUCAI <10 and no additional therapy or colectomy)
211 (50%) 73 (54%) 81 (57%) 57 (40%) 0·0079
Remission with faecal calprotectin <250 µg/g† 56/283 (20%) 17/91 (19%) 26/98 (27%) 13/94 (14%) 0·083
Additional therapy or colectomy 45 (11%) 1 (1%) 6 (4%) 38 (26%) <0·0001
First additional therapy
Anti-TNF (with or without other additional therapies) 39 (9%) 0 4 (3%) 35 (24%) <0·0001
Calcineurin inhibitor (without other additional therapy) 1 (0%) 0 0 1 (1%) 1·0‡
Immunomodulator (without other additional therapy) 4 (1%) 1 (1%) 2 (1%) 1 (1%) 0·84‡
Colectomy (with or without other additional therapy)§ 4 (1%) 0 0 4 (3%) 0·035‡
Week 12
Patients assessed for outcomes 416 (97%)* 132 (97%)* 141 (98%)* 143 (97%)* ··
Corticosteroid-free remission¶ 141 (34%) 64 (48%) 47 (33%) 30 (21%) <0·0001
Corticosteroid-naive remission in patients starting 
on mesalazine
·· 61 (46%) ·· ·· ··
Corticosteroid-free remission and faecal calprotectin 
<250 µg/g†
56/282 (20%) 25/90 (28%) 17/103 (17%) 14/89 (16%) 0·073
Corticosteroid-free remission and week 4 remission 109 (26%) 45 (34%) 40 (28%) 24 (17%) 0·0038
Ever took corticosteroid (subset starting mesalazine) ·· 35 (27%) ·· ·· ··
PUCAI <10 without additional therapy or colectomy 
but not corticosteroid-free
85 (20%) 10 (8%) 40 (28%) 35 (24%) <0·0001
Additional therapy or colectomy 82 (20%) 9 (7%) 21 (15%) 52 (36%) <0·0001
First additional therapy
Anti-TNF (with or without other additional therapies) 49 (12%) 1 (1%) 10 (7%) 38 (27%) <0·0001
Calcineurin inhibitor (without other additional therapy) 1 (0%) 0 0 1 (1%) 1·0‡
Immunomodulator (without other additional therapy) 31 (7%) 8 (6%) 11 (8%) 12 (8%) 0·75
Colectomy (with or without additional therapy) 8 (2%) 0 0 8 (6%) 0·00041
Data are n (%) or n/N (%) unless noted otherwise. PUCAI=Pediatric Ulcerative Colitis Activity Index. TNF=tumour necrosis factor. *Evaluable population excludes participants 
who discontinued the study without additional therapy or colectomy. †Remission with faecal calprotectin <250 µg/g is defined only within the subset with a stool sample. 
‡Fisher’s exact test. §One patient had colectomy with no additional therapy. ¶Week 12 corticosteroid-free remission was defined as PUCAI <10 and no corticosteroids for 
14 days without additional therapy or colectomy. p values comparing groups are from a χ² (unless noted otherwise) for categorical variables, a Mantel-Haenszel χ² test for 
ordinal variables, and ANOVA or Kruskal-Wallis test for continuous variables.
Table 2: Clinical outcomes at weeks 4 and 12 by initial therapy
colectomy in patients who initiated with intravenous 
cortico steroids, is shown in the appendix (p 18). 
For the full cohort, a total Mayo clinical and endoscopic 
severity score of less than 10 at diagnosis (OR 1·83, 95% CI 
1·10−3·06, p=0·020), proctosigmoiditis (5·00, 1·64−15·22, 
p=0·0046), relative rectal sparing (4·49, 1·75−11·47, 
p=0·0017), and rectal biopsy eosinophil peak count 
greater than 32 cells per high-power field (1·73, 1·10−2·71, 
p=0·018) were all associated with increased odds of 
week 4 clinical remission. Increasing serum albumin in 
increments of 1 g/dL (1·37, 0·99−1·90, p=0·058), showed 
a predictive trend. The model from these five parameters 
had moderate predictive accuracy (AUC 0·70, 0·64–0·75).
In focusing on the intravenous corticosteroid group and 
looking for predictors for the use of additional medical 
therapy or colectomy by week 4, the predictive model 
included total Mayo clinical and endoscopic severity score 
greater than or equal to 11 (OR 5·50, 95% CI 1·85−16·31, 
p=0·0021), decreasing serum albumin in increments of 
1 g/dL (3·86, 1·58−9·44, p=0·0031), rectal biopsy 
eosinophil count of less than or equal to 32 cells per 
high-power field (7·04, 2·21−22·41, p=0·0010), and rectal 
biopsy surface villiform changes (3·16, 1·09−9·14, 
p=0·034). These factors provided strong predictive 
accuracy (AUC 0·87, 0·80–0·94).
Table 4 shows the multivariable model of baseline 
and week 4 characteristics associated with week 12 
corticosteroid-free remission for all initial therapy groups 
and additional therapy or colectomy for patients treated 
with intravenous corticosteroids. For the full cohort 
and for each initial treatment group, the factor most 
consistently associated with corticosteroid-free remission 
was week 4 clinical remission, with the smallest effect 
with mesalazine and the largest effect with intravenous 
corticosteroids. For the full cohort, other baseline 
predictive factors for corticosteroid-free remission 
included PUCAI less than 35 and increasing serum 
albumin by 1 g/dL increments in children younger 
12 years (table 4).
By focusing on the intravenous corticosteroid group 
and looking for predictors for the use of additional 
medical therapy or colectomy by week 12, we identified a 
predictive model that included initial total Mayo score 
greater than or equal to 11 (factor included because of its 
clinical relevance), rectal biopsy eosinophil count less 
than or equal to 32 cells per high-power field, the 
presence of surface villiform changes, and the absence of 
remission by week 4 (table 4). Together, these factors 
provided strong predictive accuracy (AUC 0·89, 95% CI 
0·83–0·95). If the analysis is limited to examination of 
patients who received intravenous cortico steroids and 
then infliximab or a calcineurin inhibitor or colectomy 
(patients taking immunomodulators were excluded) by 
week 12, the predictive model is essentially the same as 
that for week 4, because 37 of the 40 participants who 
initiated on intravenous corticosteroids and received 

















Age (years) 12·2 (3·5) 12·9 (3·1) 12·9 (3·1) 0·11
Sex 0·57
Girls 72 (51%) 91 (47%) 44 (54%) ··
Boys 69 (49%) 102 (53%) 38 (46%) ··
Non-white race 24/139 (17%) 26/190 (14%) 15/79 (19%) 0·48
Body-mass index Z score –0·1 (1·2) –0·2 (1·2) –0·5 (1·6) 0·13
Admitted to hospital at baseline 33 (23%) 73 (38%) 55 (67%) <0·0001
Baseline characteristics
Total PUCAI (range 0−85 in 
increments of 5)
42·0 (19·3) 50·6 (18·4) 62·1 (17·2) <0·0001
10−30 (mild) 50 (35%) 42 (22%) 6 (7%) <0·0001
35−60 (moderate) 62 (44%) 90 (47%) 30 (37%) ··
≥65 (severe) 29 (21%) 61 (32%) 46 (56%) ··
Abdominal pain 108 (77%) 163 (84%) 73 (89%) 0·041
Diarrhoea 121 (86%) 181 (94%) 82 (100%) 0·00037
Rectal bleeding 127 (90%) 181 (94%) 78 (95%) 0·29
Total Mayo score (0−12) 7·0 (2·4) 7·7 (2·3) 9·3 (2·2) <0·0001
≥10 23 (16%) 51 (26%) 42 (51%) <0·0001
≥11 10 (7%) 23 (12%) 36 (44%) <0·0001
Mayo endoscopic subscore (0−3) 2·1 (0·7) 2·1 (0·7) 2·5 (0·5) <0·0001
Partial Mayo score (0−9) 4·9 (2·0) 5·6 (1·9) 6·8 (1·9) <0·0001
Disease extent 0·00041
Proctosigmoiditis 13 (9%) 15 (8%) 0 ··
Left-sided colitis 21 (15%) 19 (10%) 3 (4%) ··
Extensive, pancolitis, 
or unassessable
107 (76%) 159 (82%) 79 (96%) ··
Relative rectal sparing 19/141 (13%) 14/192 (7%) 4/82 (5%) 0·053
Coecal patch 16/135 (12%) 9/179 (5%) 4/72 (6%) 0·059
Non-specific macroscopic gastritis 26/137 (19%) 53/189 (28%) 31/82 (38%) 0·0089
Rectal biopsy eosinophilic 
inflammation (>32 cells per 
high-power field)
73/125 (58%) 105/162 (65%) 26/69 (38%) 0·00066
Rectal biopsy surface villiform 
changes
35/125 (28%) 57/161 (35%) 39/68 (57%) 0·00025
Rectal biopsy basal plasmacytosis 52/116 (45%) 86/152 (57%) 32/58 (55%) 0·14
Haemoglobin (g/dL) 11·9 (1·9) 11·5 (2·2) 10·5 (2·4) <0·0001
<10 19/131 (15%) 42/179 (23%) 35/81 (43%) <0·0001
Platelet count (× 10⁹ cells per L) 362 (286−434) 355 (297−473) 410 (345−496) 0·0092
>500 18/130 (14%) 38/178 (21%) 20/80 (25%) 0·10







>12 23/127 (18%) 42/178 (24%) 31/81 (38%) 0·0040
Erythrocyte sedimentation rate 
(mm/h)
22 (11−39) 23 (12−38) 36 (22−53) 0·00018
≤20 61/128 (48%) 82/171 (48%) 17/75 (23%) 0·00016
>40 30/128 (23%) 38/171 (22%) 31/75 (41%) ··
CRP or hsCRP >2 × ULN 24/101 (24%) 37/142 (26%) 34/67 (51%) <0·0001
Albumin (g/dL) 3·9 (0·6) 3·6 (0·7) 3·3 (0·7) <0·0001
<3·5 32/140 (23%) 65/189 (34%) 40/81 (49%) 0·00028
(Table 3 continues on next page)
estimates are shown in the appendix (pp 19, 20), as are 
ROC curves and calibration plots (pp 23, 24).
In our internal validation, the results from bootstrapping 
and multiple imputation were generally supportive of the 
final selected models, as described in the appendix (p 8, 9, 
21, 22). The size of the ORs was attenuated (but with 
p<0·05) in the imputation models for proctosigmoiditis 
(week 4 and full cohort), relative rectal sparing (week 4 
full cohort and oral corticosteroids), and rectal biopsy 
eosinophil peak count (week 4 additional therapy among 
patients who started on intravenous corticosteroid).
Discussion
PROTECT is, to our knowledge, the first multicentre 
inception cohort study to report factors associated with 
early responses to standardised first-line therapy in 
treatment-naive paediatric ulcerative colitis. Our data 
reveal a sobering early course for children with new-onset 
ulcerative colitis. Corticosteroid-free remission at week 12 
after diagnosis without the need for therapy with 
immunomodulators, anti-TNF agents, or colectomy 
occurred in 48% of children initially treated with 
mesalazine for mild to lower moderate intensity 
disease. Week 12 remission was only achieved 
by 33% of patients with moderate disease who initially 
started on oral corticosteroids, and this value was even 
lower at 21% among those admitted to hospital with 
severe disease who initially started on intravenous 
corticosteroids. It is possible that these numbers were 
affected b y a n a ggressive a ttempt t o l ower a nd t hen 
stop corticosteroid use by 10 weeks after diagnosis.
Comparison of our results to outcomes in adults 
following mesalazine or corticosteroid therapy is 
difficult gi ven th at ou r st udy po pulation wa s ne wly 
diagnosed and treatment naive and we used 
standardised dosing regimens. Compared with previous 
adult and paediatric studies, we used a relatively high 
mesalazine dosing schedule of about 67 mg/kg per day 
(maximum 4 g) because previous work in adults has 
suggested improved outcomes with increased dosing 
schedules.21 The proportions of patients achieving a 
response to a first course of corticosteroids by 4 weeks 
in adults with ulcerative colitis (not necessarily at 
diagnosis) are 40−50%,7,10 which is similar to our results 
in children. In those studies,7,10 higher initial Mayo 
scores and extensive disease were predictors of 
non-response and need for additional medical therapy 
or colectomy. Our finding o f 2 6% o f c hildren i n t he 
intravenous corticosteroid group needing additional 
medical therapy is similar to that from a previous 
report2 on children with acute severe colitis (29%) who 
were treated with intravenous corticosteroids at 
presentation or following an exacerbation of previously 
diagnosed disease.
Follow-up endoscopic evaluation was not part of the 
treatment protocol or routinely done by week 12 and 
therefore endoscopic improvement or healing rates are 
 
not available. However, we did longitudinal measurement 
of faecal calprotectin as a surrogate of mucosal healing. 

















(Continued from previous page)
Faecal calprotectin* (µg/g)
Patients with data 78 110 48







Faecal osteoprotegerin (pg/mL)* 119 (31–1460) 508 (31–3220) 1208 (205–6427) 0·015
>1000 14/54 (26%) 39/90 (43%) 17/33 (52%) 0·049







<20 (deficient) 12/133 (9%) 16/173 (9%) 11/75 (15%) 0·37
pANCA (EU/mL) 
Positive titre 89/134 (66%) 110/174 (63%) 54/77 (70%) 0·56
≥100 22/134 (16%) 33/174 (19%) 19/77 (25%) 0·34







Positive titre 5/134 (4%) 12/174 (7%) 3/77 (4%) 0·45†
≥12 24/134 (18%) 33/174 (19%) 22/77 (29%) 0·14
Week 4 characteristics
Week 4 remission 109 (77%) 91 (47%) 8 (10%) <0·0001
Week 4 remission with faecal 
calprotectin* <250 µg/g
35/100 (35%) 19/135 (14%) 1/46 (2%) <0·0001
Week 4 additional therapy or 
colectomy
0 0 45 (55%) <0·0001
Week 4 PUCAI score (0−85 in increments of 5)
Patients with data 138 193 76
Mean (SD) 4·8 (7·3) 12·6 (15·6) 20·1 (20·0) <0·0001
Week 4 partial Mayo score (range 0−9)
Patients with data 120 168 67
Mean (SD) 0·7 (1·1) 1·5 (1·7) 2·3 (2·2) <0·0001
Week 4 albumin (g/dL)
Patients with data 104 149 67
Mean (SD) 4·3 (0·4) 4·2 (0·5) 3·8 (0·6) <0·0001
Week 4 CRP or hsCRP >2 × ULN 1/85 (1%) 6/109 (6%) 9/55 (16%) 0·0018†
Week 4 erythrocyte sedimentation rate (mm/h)
Patients with data 101 135 66
Median (IQR) 10 (6−17) 9 (6−18) 18 (8−35) 0·00085
Week 4 faecal calprotectin* (µg/g)
Patients with data 100 135 46







Data are n (%), n/N (%), n, mean (SD), or median (IQR), unless noted otherwise. p values comparing groups are from 
a χ² test (unless noted otherwise) for categorical variables, a Mantel-Haenszel χ² test for ordinal variables, and ANOVA or 
Kruskal-Wallis test for continuous variables. PUCAI=Pediatric Ulcerative Colitis Activity Index. CRP=C-reactive protein. 
ULN=upper limit of normal. EU=endotoxin units. pANCA=perinuclear anti-neutrophil cytoplasmic antibody. 
OmpC=outer membrane precursor protein C. *Results limited to stool collected prior to 4 days of initial treatment, and 
before or after colonoscopy cleanout. †Fisher’s exact test.
Table 3: Baseline and week 4 clinical and demographic characteristics by week 12 outcome
stool sample had a faecal calprotectin greater than or 
equal to 250 µg/g at diagnosis. At week 12, 20% of all 
patients from whom stool was obtained had faecal 
calprotectin less than 250 µg/g and were in corticosteroid-
free remission, ranging from 28% of those initially 
treated with mesalazine to 17% of those treated with oral 
corticosteroids, and 16% of those treated with intravenous 
corticosteroids. These data suggest that mucosal healing 
can occur by week 12 in patients in clinical and 















Model sample size 403/409 (99%) 116/129 (90%) 139/139 (100%) 119/141 (84%) 119/141 (84%)
Number of events 140/403 (35%) 57/116 (49%) 47/139 (34%) 26/119 (22%) 42/119 (35%)
Baseline predictors
Lower PUCAI ·· ·· ·· ·· ··
<35 2·44 (1·41–4·22), 
p=0·0015
·· ·· ·· ··
<45 ·· ·· 4·38 (1·81–10·60), 
p=0·0011
·· ··
Total Mayo score ≥11 ·· ·· ·· ·· 2·59 (0·93–7·21), 
p=0·068
Higher albumin per 1 g/dL increase (interaction with age)†
Age <12 years 4·05 (1·90–8·64), 
p=0·00030
·· ·· ·· ··
Age ≥12 years 1·13 (0·74–1·71), 
p=0·57
·· ·· ·· ··
Haemoglobin ≥12 g/dL ·· 2·19 (0·96–4·97), 
p=0·062
·· ·· ··
Rectal biopsy eosinophil peak count 
≤32 cells per high-power field
·· ·· ·· ·· 4·55 (1·62–12·78), 
p=0·0040
Rectal biopsy surface villiform changes
No changes ·· ·· ·· 2·71 (0·97–7·56), 
p=0·057
··
Changes ·· ·· ·· ·· 3·05 (1·09–8·56), 
p=0·034
Week 4 remission









No ·· ·· ·· ·· 30·28 (6·36–144·20), 
p<0·0001
Assessments of model fit
AUC 0·79 (0·74–0·84) 0·70 (0·61–0·79) 0·78 (0·71–0·86) 0·77 (0·67–0·88) 0·89 (0·83–0·95)
Adjusted AUC 0·78 (0·73–0·83) 0·70 (0·61–0·79) 0·78 (0·71–0·86) 0·77 (0·67–0·88) 0·88 (0·82–0·94)
R² 0·31 0·18 0·32 0·26 0·54
Sensitivity 41% (33–50) 54% (41–68) 40% (26–56) 62% (41–80) 71% (55–84)
Specificity 89% (85–92) 61% (47–73) 93% (86–98) 86% (77–92) 86% (76–93)
Positive predictive value 67% (56–76) 57% (43–71) 76% (55–91) 55% (36–74) 73% (57–86)
Negative predictive value 74% (69–79) 58% (45–70) 75% (66–83) 89% (81–95) 85% (75–92)
Data are n/N (%), odds ratio (95% CI), or % (95% CI) unless noted otherwise. Further models for the full cohort identified an interaction between mild baseline PUCAI (10–30) 
and week 4 remission (p=0·05), indicating that the effect of week 4 remission on week 12 remission is less strong for participants with a mild baseline PUCAI. The interaction 
was not included in the model because there was no improvement in the model AUC. Potential covariates were excluded from the model on the basis of internal validation: 
ANCA positivity was excluded in the mesalazine and oral corticosteroid groups because of clinical inconsistency between subgroups and across assessment times, whereas 
OmpC <12 EU/mL was excluded from analysis of additional therapy or colectomy in the intravenous corticosteroid group because of the absence of association in the 
multiple imputation model. AUC=area under the curve. Adjusted AUC=AUC with bootstrap adjustment for optimism of model estimation. PUCAI=Pediatric Ulcerative Colitis 
Activity Index. EU=endotoxin units. ANCA= anti-neutrophil cytoplasmic antibodies. OmpC=outer membrane precursor protein C. *N is the number evaluable at week 12 and 
with no protocol violations. †For the full cohort, p=0·004 for the interaction between age <12 years and albumin.
Table 4: Multivariable logistic regression models of week 12 outcomes by treatment type
in patients with new-onset ulcerative colitis treated with 
standardised mesalazine or corticosteroid therapy.
Our exploratory modelling supported previous 
observations of the importance of initial disease severity 
and extent in predicting disease course in both children 
and adults.4−7,22,23 In our study and in previous work,6,7 
initial serum albumin was associated with disease 
outcome, with lower concentrations being associated 
with worse outcomes. Our results also support the 
usefulness of baseline total Mayo clinical and endoscopic 
severity score in identifying patients who are less likely to 
achieve week 4 remission with corticosteroids alone.
We found that the number of eosinophils on rectal biopsy 
correlated with clinical outcomes. On the basis of previous 
observations,14 we classified r ectal b iopsy e osinophilia a s 
peak eosinophil count less than or equal to 32 cells per 
high-power field or as peak eosinophil count greater than 
32 cells per high-power field;14 more than half of our study 
participants had counts in the higher classification. 
Mucosal eosinophilia in ulcerative colitis has been reported 
previously in both adults24−26 and children.27,28 Although 
previous paediatric data revealed a positive correlation 
between rectosigmoid eosinophil numbers and disease 
severity,27 adult studies have suggested that decreased 
eosinophil counts at rectal biopsy are associated with 
medically refractory disease.24,26 Notably, the adult studies 
included patients on therapy, including corticosteroids, 
which might have reduced tissue eosinophilia, whereas 
our study included only treatment-naive patients. The role 
of eosinophils in disease pathogenesis continues to be 
explored. Another study suggested a role for type 2 immune 
responses, including tissue eosinophilia, in improved 
responses to therapy in paediatric ulcerative colitis and 
wound healing.29 Rectal expression of a panel of type 2 
immune genes, including interleukin 5 and interleukin 13, 
measured at diagnosis of paediatric ulcerative colitis was 
associated with a higher proportion of patients achieving 
steroid-free remission. The paradoxical finding f rom o ur 
work that decreased tissue eosinophil numbers were 
associated with greater likelihood of refractory disease thus 
remains unexplained, but is consistent with earlier adult 
and more recent paediatric studies.24,26
We also noted that surface villiform changes on rectal 
biopsy were associated with the need for additional medical 
therapy or colectomy in patients initially treated with 
intravenous corticosteroids. To our knowledge this 
association has not been reported previously and might 
reflect t he n ature o f e pithelial d amage i n s evere c linical 
disease. This result was not simply a reflection of higher 
clinical and endoscopic severity, because a multivariable 
model that included total Mayo score identified a n 
independent association between surface villiform 
changes and increased likelihood of treatment escalation. 
Future studies using concurrent rectal microbial 
community and gene expression data should seek to 
determine the specific biological pathways associated with 
this adverse histological feature.
Our study has several strengths, but also some 
limitations. Strengths include the large multicentre 
prospective inception cohort design, standardised 
guidelines for initial therapy, and well validated clinical 
outcome measures. However, patient selection was not 
population-based and disease severity distribution might 
have been biased at selected centres that enrolled more 
or less ill patients. Therefore, the roughly one-third 
distribution of mild, moderate, and severe disease, 
respectively, noted in our inception cohort might not be 
representative of all paediatric ulcerative colitis. Despite 
the use of protocol-guided standardised initial therapy 
based on disease severity, the ultimate treatment 
selection was left to the discretion of the clinician and 
patients’ families, and the protocol guidelines were 
initiated successfully in two-thirds of our study 
population. The predictive models for initial treatment 
subgroups are based on a smaller sample size than the 
entire cohort. We did not do external validation for the 
presented prediction models. Additionally, the models 
could potentially be affected by the pattern of missing 
data across the covariates. The lower than anticipated 
collection rate for stool samples at all timepoints 
limited our ability to use faecal calprotectin and faecal 
osteoprotegerin in the final predictive modelling. Novel 
interventions will be needed to improve stool collection 
in future studies. Similar constraints occurred with the 
low availability of standard-of-care CRP measurements 
at baseline.
We have documented early response rates to standardised 
mesalazine and corticosteroids in phenotyped subgroups 
of children with newly diagnosed ulcerative colitis, and 
identified candidate predictors for early remission or the 
need for medical therapy beyond mesalazine and 
corticosteroids. Our results show that clinical activity 
indices, including PUCAI and Mayo score, can be 
combined with serum albumin and specific histological 
features of rectal biopsies to judge the likelihood of success 
for first-line therapies, and that week 4 remission is a 
crucial juncture to guide additional therapies. These data 
suggest that additional therapeutic interventions could be 
warranted to improve early outcomes, especially in 
children presenting with severe disease and requiring 
treatment with intravenous corticosteroids.
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